Cite
Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
MLA
Parra-Izquierdo, Iván, et al. “Janus Kinase Inhibitors Ruxolitinib and Baricitinib Impair Glycoprotein-VI Mediated Platelet Function.” Platelets, vol. 33, no. 3, Apr. 2022, pp. 404–15. EBSCOhost, https://doi.org/10.1080/09537104.2021.1934665.
APA
Parra-Izquierdo, I., Melrose, A. R., Pang, J., Lakshmanan, H. H. S., Reitsma, S. E., Vavilapalli, S. H., Larson, M. K., Shatzel, J. J., McCarty, O. J. T., & Aslan, J. E. (2022). Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. Platelets, 33(3), 404–415. https://doi.org/10.1080/09537104.2021.1934665
Chicago
Parra-Izquierdo, Iván, Alexander R. Melrose, Jiaqing Pang, Hari Hara Sudhan Lakshmanan, Stéphanie E. Reitsma, Sai Hitesh Vavilapalli, Mark K. Larson, Joseph J. Shatzel, Owen J. T. McCarty, and Joseph E. Aslan. 2022. “Janus Kinase Inhibitors Ruxolitinib and Baricitinib Impair Glycoprotein-VI Mediated Platelet Function.” Platelets 33 (3): 404–15. doi:10.1080/09537104.2021.1934665.